Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

24 of 26+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Austria· EU contribution €1,500,000· until Jun 2032· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Switzerland· EU contribution €150,000· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €150,000· until Jan 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Italy· EU contribution €193,643· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spain· EU contribution €194,075· until Dec 2027· 2 countries

5 of 22 running projects, newest first. Listed amounts together: €71.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Eli Lilly and Company· Source

• Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

  NCT07718126· West China Hospital· Source

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 173
• Genome-Wide Association Study 49

• Integrated Transcriptomic and Single-Cell Analysis Reveals Shared Macrophage-Associated Inflammatory Signatures in MASLD/NAFLD and Rheumatoid Arthritis.

  Int J Mol Sci, Oct 2026

• A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver disease.

  Nat Genet, Sept 2026

• An lncRNA-aware single-cell framework with donor-level validation identifies reproducible MEG3 enrichment in human liver sinusoidal endothelial cells.

  Funct Integr Genomics, Sept 2026

• Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics.

  Cell Genom, Aug 2026

• Identification of glutathione metabolism-related biomarkers in non-alcoholic fatty liver disease based on single-cell and bulk RNA sequencing.

  BMC Med Genomics, Jul 2026

• Bisphenol A drives the comorbidity of non-alcoholic fatty liver disease and osteoarthritis by targeting RHOB: Integrated multi-omics, single-cell analysis, and experimental validation.

  Exp Gerontol, Jul 2026

• Potential targets of baicalein in macrophages revealed by bulk and single cell RNA sequencing analysis.

  Naunyn Schmiedebergs Arch Pharmacol, Jun 2026

• Integrative Single-Cell Transcriptomic, Mendelian Randomization and In Silico Perturbation Analyses Prioritize MUC20 as a Candidate Gene Associated with Osteoporosis and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Liver-Bone Axis.

  Int J Mol Sci, Jun 2026

• Identification of Estrogen-Related Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease Through Machine Learning and Single-Cell Analysis.

  Clin Transl Gastroenterol, Jun 2026

• A fluorescence-based high-content imaging workflow for multi-parametric lipid droplet phenotyping via Oil Red O fluorescence.

  Methods, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.